Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
21
PPBT Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
-10.66%
Day range:
$0.67 - $0.73
52-week range:
$0.53 - $5.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.19x
Volume:
174.6K
Avg. volume:
632.7K
1-year change:
-79.49%
Market cap:
$6.4M
Revenue:
--
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingPurple Biotech Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.00, Purple Biotech Ltd. has an estimated upside of 4705.65% from its current price of $0.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $34.00 representing 100% downside risk from its current price of $0.71.
Fair Value
-
According to the consensus of 1 analyst, Purple Biotech Ltd. has 4705.65% upside to fair value with a price target of $34.00 per share.
PPBT vs. S&P 500
-
Over the past 5 trading days, Purple Biotech Ltd. has underperformed the S&P 500 by -5.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Purple Biotech Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Purple Biotech Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Purple Biotech Ltd. reported revenues of --.
Earnings Growth
-
Purple Biotech Ltd. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Purple Biotech Ltd. reported earnings per share of -$0.29.
Enterprise value:
-3.8M
EV / Invested capital:
-0.11x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$191.6K
Return On Assets:
-9.1%
Net Income Margin (TTM):
--
Return On Equity:
-10.31%
Return On Invested Capital:
-10.25%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$199K | -$194K | -$191.6K | -$49K | -$58.3K | |
| Operating Income | -$22.6M | -$16.3M | -$5.1M | -$2.1M | -$1.4M | |
| EBITDA | -$22.4M | -$16.1M | -$4.9M | -$2.1M | -$1.3M | |
| Diluted EPS | -$20.79 | -$8.94 | -$1.02 | -$0.38 | -$0.29 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $34.3M | $16.7M | $6.9M | $10.8M | |
| Total Assets | -- | $58.5M | $45.3M | $35.1M | $39.1M | |
| Current Liabilities | -- | $5.9M | $6.2M | $5.5M | $6.1M | |
| Total Liabilities | -- | $6.4M | $6.6M | $5.6M | $6.2M | |
| Total Equity | -- | $52.1M | $38.7M | $29.5M | $32.8M | |
| Total Debt | -- | $550K | $370K | $222K | $256K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.5M | -$17M | -$6.5M | -$3.2M | -$1M | |
| Cash From Investing | $21.1M | $183K | $606.3K | -$3K | $325.1K | |
| Cash From Financing | $1.4M | $7.1M | $10M | $2.1M | $5.6M | |
| Free Cash Flow | -$18.5M | -$17M | -$6.5M | -$3.2M | -$1M | |
PPBT
Sector
Market Cap
$6.4M
$27.9M
Price % of 52-Week High
13.61%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-197.55%
-1.49%
1-Year Price Total Return
-79.49%
-16.66%
Beta (5-Year)
0.599
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.76
200-day SMA
Sell
Level
$1.78
Bollinger Bands (100)
Sell
Level
0.41 - 1.69
Chaikin Money Flow
Buy
Level
271.9K
20-day SMA
Sell
Level
$0.79
Relative Strength Index (RSI14)
Sell
Level
40.69
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-82.0903
50-day SMA
Sell
Level
$0.75
MACD (12, 26)
Buy
Level
0.14
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-754.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.532)
Buy
CA Score
(Annual)
Level (-0.2016)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.9779)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
Stock Forecast FAQ
In the current month, PPBT has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PPBT average analyst price target in the past 3 months is $34.00.
-
Where Will Purple Biotech Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Purple Biotech Ltd. share price will rise to $34.00 per share over the next 12 months.
-
What Do Analysts Say About Purple Biotech Ltd.?
Analysts are divided on their view about Purple Biotech Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Purple Biotech Ltd. is a Sell and believe this share price will drop from its current level to $34.00.
-
What Is Purple Biotech Ltd.'s Price Target?
The price target for Purple Biotech Ltd. over the next 1-year time period is forecast to be $34.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PPBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Purple Biotech Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PPBT?
You can purchase shares of Purple Biotech Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Purple Biotech Ltd. shares.
-
What Is The Purple Biotech Ltd. Share Price Today?
Purple Biotech Ltd. was last trading at $0.68 per share. This represents the most recent stock quote for Purple Biotech Ltd.. Yesterday, Purple Biotech Ltd. closed at $0.71 per share.
-
How To Buy Purple Biotech Ltd. Stock Online?
In order to purchase Purple Biotech Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PPBT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PPBT
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
0.19x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
PPBT
Sector
Revenue growth
--
4.62%
Earnings growth
24.79%
10.5%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$0.26
-$0.21
Profitability
PPBT
Sector
Profitability FY 2024
-$186.9K
$3.6M
Return on invested capital
-10.25%
-31.87%
Return on assets
-9.1%
-28.18%
Return on equity
-10.31%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
PPBT
Sector
Total cash
$10.5M
$26.4M
Short term investments
$1.1M
$25.7M
Total assets
$37M
$76.9M
Long term debt
$256K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
